公开(公告)号：US20230138310A1

公开(公告)日：2023-05-04

申请号：US17759807

申请日：2020-03-26

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  FRONTIER BIOTECHNOLOGIES INC.

发明人： Hong LIU ,  Jian LI ,  Wenhao DAI ,  Jingjing PENG ,  Xiong XIE ,  Shulei HU ,  Chunpu LI ,  Yechun XU ,  Haitao YANG ,  Leike ZHANG ,  Haixia SU ,  Hualiang JIANG ,  Zhenming JIN ,  Gengfu XIAO ,  Kaixian CHEN

IPC分类号： C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D401/12 ,  C07D411/12 ,  C07D471/04 ,  C07D207/12 ,  A61P31/14

摘要： Use of an aldehyde-based compound as represented by general formula I, a pharmaceutical composition, a pharmaceutical salt, an enantiomer, a diastereomer and a racemic compound thereof as a novel coronavirus 2019 (2019-nCov) 3CL protease inhibitor in preparation of a medicament for treating and/or preventing and relieving respiratory tract infections, pneumonia and other related diseases caused by the novel coronavirus infection 2019.

公开(公告)号：US20230133600A1

公开(公告)日：2023-05-04

申请号：US17796076

申请日：2021-01-28

申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： Hong LIU ,  Jian LI ,  Jingjing PENG ,  Xiong XIE ,  Wenhao DAI ,  Shulei HU ,  Chunpu LI ,  Leike ZHANG ,  Zhenming JIN ,  Yechun XU ,  Gengfu XIAO ,  Haitao YANG ,  Fang BAI ,  Xi CHENG ,  Hualiang JIANG ,  Kaixian CHEN

IPC分类号： A61K31/404 ,  A61K31/4412 ,  A61K31/4025 ,  A61K31/498 ,  A61K31/4709 ,  A61K31/443 ,  A61K31/4545 ,  A61K31/454 ,  A61K31/4535 ,  A61K31/453 ,  A61K31/4525 ,  A61K31/4439 ,  A61K31/437 ,  A61K31/4155

摘要： A class of ketoamide-based compounds, in particular, a ketoarnide-based compound as represented by general formula A is provided. The ketoamide compound may be used as a 2019 novel coronavirus (2019-nCov) 3 CL protease inhibitor and/or human cathepsin L inhibitor, and/or may be used in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infection, pneumonia and other related diseases caused by 2019 novel coronavirus infection. Pharmaceutical compositions of the class of compounds, pharmaceutical salts, enantiomeric forms, diastereoisomers and racemic compounds thereof in the preparation of a medicament for treating and/or preventing and relieving respiratory tract infections and other related diseases caused by the 2019 novel coronavirus infection are also provided.